Anisimov V N, Popovich I G, Zabezhinskiĭ M A, Rozenfel'd S V, Khavinson V Kh, Semenchenko A V, Iashin A I
Vopr Onkol. 2005;51(1):93-8.
Female senescence accelerated mice SAMP-1. (prone) and SAMR-1 (resistant) were exposed 5 times a week monthly to melatonin (with drinking water 20mg/ml during the night hours) or to s.c. injections of epitalon (Ala-Glu-Asp-Gly) at a single dose 1mkg/mouse. Control mice were intact or exposed to injection of 0.1 ml normal saline. The body weight and temperature, food consumption, estrous function were monitored regularly. The life span and tumor incidence were evaluated as well. As age advanced, the weight increased whereas food consumption and body temperature did not change. There was no significant substrain difference in these parameters. Exposure to melatonin or epitalon also failed to influence those indices. As age advanced, the incidence of irregular estrous cycles increased both in SAMP-1 and SAMR-1, whereas the treatment with both melatonin and epitalon prevented such disturbances. SAMP-1 revealed some features of accelerated aging as compared to SAMR-1. The mean life span of the 10% of the last survivors among treated SAMP-1 was shorter than that of SAMR-1, aging rate increased and mortality doubling time decreased. There was a direct correlation between body mass of the two substrains at the age of 3 and 12 months matched by body mass increase and longer life span. Melatonin or epitalon treatment was followed by longer mean and maximum survival in the 10% of the last survivors among SAMP-1. Melatonin involved decreased aging rate and increased mortality doubling time. Malignant lymphomas predominated in SAM without any significant difference in frequency between the substrains. While melatonin failed to influence tumor incidence or term of detection in SAMP-1, neither did epitalon affect frequency. However, it was followed by longer survival in tumor-free animals. No link between melatonin or epitalon treatment, on the one hand, and carcinogenesis, on the other, was reported in SAMR-1.
雌性衰老加速小鼠SAMP-1（易衰老）和SAMR-1（抗衰老）每月每周5次暴露于褪黑素（夜间饮用含20mg/ml的水）或皮下注射表柔比星（Ala-Glu-Asp-Gly），剂量为1mkg/小鼠。对照小鼠未处理或注射0.1ml生理盐水。定期监测体重、体温、食物消耗和发情功能。还评估了寿命和肿瘤发生率。随着年龄增长，体重增加，而食物消耗和体温没有变化。这些参数在亚系间无显著差异。暴露于褪黑素或表柔比星也未能影响这些指标。随着年龄增长，SAMP-1和SAMR-1的不规则发情周期发生率均增加，而褪黑素和表柔比星治疗均可预防此类紊乱。与SAMR-1相比，SAMP-1表现出一些加速衰老的特征。治疗后的SAMP-1中最后10%存活者的平均寿命短于SAMR-1，衰老率增加，死亡倍增时间缩短。3个月和12个月时，两个亚系的体重与体重增加和更长寿命呈直接相关。褪黑素或表柔比星治疗后，SAMP-1中最后10%存活者的平均和最大生存期延长。褪黑素降低了衰老率，增加了死亡倍增时间。恶性淋巴瘤在SAM中占主导地位，亚系间频率无显著差异。虽然褪黑素未能影响SAMP-1的肿瘤发生率或检测期限，但表柔比星也未影响频率。然而，它使无肿瘤动物的生存期延长。在SAMR-1中，未报告褪黑素或表柔比星治疗与致癌作用之间的联系。
